Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1971 1
1972 1
1990 1
1994 2
1995 1
1996 1
1997 1
2003 1
2004 1
2005 4
2006 4
2007 12
2008 3
2009 8
2010 7
2011 10
2012 7
2013 10
2014 12
2015 24
2016 23
2017 32
2018 24
2019 19
2020 25
2021 31
2022 33
2023 31
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: grande e. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Among authors: grande e. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thåström A, Grande E; IMvigor130 Study Group. Galsky MD, et al. Among authors: grande e. Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0. Lancet. 2020. PMID: 32416780 Clinical Trial.
In Reply.
Grande E, Molina-Cerrillo J, Alonso-Gordoa T. Grande E, et al. Oncologist. 2020 Aug;25(8):e1259. doi: 10.1634/theoncologist.2020-0336. Epub 2020 Jun 16. Oncologist. 2020. PMID: 32436340 Free PMC article.
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, Kristeleit H, Farrugia D, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Godeaux O, López-Fauqued M, Salaun B, Heineman TC, Oostvogels L; Zoster-028 Study Group. Vink P, et al. Among authors: grande e. Cancer. 2019 Apr 15;125(8):1301-1312. doi: 10.1002/cncr.31909. Epub 2019 Feb 1. Cancer. 2019. PMID: 30707761 Free PMC article. Clinical Trial.
Antiepileptic drugs: Role in paediatric poisoning.
Ferranti S, Grande E, Gaggiano C, Grosso S. Ferranti S, et al. Among authors: grande e. J Paediatr Child Health. 2018 May;54(5):475-479. doi: 10.1111/jpc.13833. Epub 2018 Jan 2. J Paediatr Child Health. 2018. PMID: 29292550 Review.
Novel Tyrosine Kinase Targets in Urothelial Carcinoma.
Torres-Jiménez J, Albarrán-Fernández V, Pozas J, Román-Gil MS, Esteban-Villarrubia J, Carrato A, Rosero A, Grande E, Alonso-Gordoa T, Molina-Cerrillo J. Torres-Jiménez J, et al. Among authors: grande e. Int J Mol Sci. 2021 Jan 13;22(2):747. doi: 10.3390/ijms22020747. Int J Mol Sci. 2021. PMID: 33451055 Free PMC article. Review.
BRAF Mutated Colorectal Cancer: New Treatment Approaches.
Molina-Cerrillo J, San Román M, Pozas J, Alonso-Gordoa T, Pozas M, Conde E, Rosas M, Grande E, García-Bermejo ML, Carrato A. Molina-Cerrillo J, et al. Among authors: grande e. Cancers (Basel). 2020 Jun 14;12(6):1571. doi: 10.3390/cancers12061571. Cancers (Basel). 2020. PMID: 32545884 Free PMC article. Review.
304 results